Clinical-stage oncology company X4 Pharmaceuticals secured a USD 115 million loan facility from Hercules Capital, a business development company focused on venture lending. The initial drawdown was USD 22.5 million. This brings total funds raised to USD 392.1 million.

The funding will be used to support X4 Pharmaceuticals to prepare for the potential commercial launch of mavorixafor, continue to develop the drug for certain chronic neutropenic disorders, and create expanded future options beyond equity capital markets, including potentially monetizing a priority review voucher.

X4 Pharmaceuticals specializes in developing therapies for rare immune system diseases. Its lead clinical candidate, mavorixafor, is a small-molecule antagonist targeting the chemokine receptor, CXCR4. It is an oral, once-daily therapy designed to increase the mobilization of white blood cells and provide therapeutic benefits for chronic neutropenic disorders, including the rare primary immunodeficiency known as the WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. The company's core research activities and expertise in CXCR4 and immune system biology are conducted at its corporate headquarters in Boston, Massachusetts, with a research center of excellence in Vienna, Austria.